Filing Flows › Emmaus Life Sciences (EMMA) › Q2 2025
Emmaus Life Sciences (EMMA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Emmaus Life Sciences (EMMA) reported revenue of $2.8M for the second quarter 2025 (Q2 2025), -48% from a year earlier and +17% from the quarter before. Operating margin was -13.1%, net loss $1.1M (40.3% of revenue).
Emmaus Life Sciences, Q2 2025: revenue $2.8M (-48% year over year), operating margin -13.1%, net loss $1.1M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | +17% | -48% |
| Operating profit | −$370K | — | — |
| Net earnings | −$1.1M | — | — |
| Operating cash flow | −$2.9M | -1142% | — |
What changed
Revenue was $2.8M in Q2 2025, down 48% year over year and up 17% from the previous quarter. Endari was the largest line at 99% of revenue. Endari lost $2.6M year over year (down 48%), 100% of the total change.
Gross margin was 94.7%, down 0.8 points from a year earlier. Operating costs exceeded revenue by $370K, an operating margin of -13.1%. Operating expenses fell 33% while revenue fell 48%. The quarter ended with a net loss of $1.1M, narrower than the previous quarter's $2.3M loss. Net interest and other expense of $1.4M was the main reason.
Operating cash flow was −$2.9M. Non-cash charges added back $4K of depreciation. Working capital and other items used $1.8M.
Questions
What was Emmaus Life Sciences' revenue in the second quarter 2025?
Emmaus Life Sciences (EMMA) reported revenue of $2.8M for the second quarter 2025 (Q2 2025), -48% from a year earlier and +17% from the quarter before.
Was Emmaus Life Sciences profitable in the second quarter 2025?
Operating loss was $370K (-13.1% of revenue) and net loss $1.1M.